RayKnowChina Research Map
Shortlist

Not yet recruitingPancreatic cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07415525, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. (5)No prior anti-tumor treatment for the studied disease, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.

    Inclusion criterion 5

    (10)Female subjects of childbearing potential or male subjects with female partners of childbearing potential must use effective contraception throughout the treatment period and for 6 months after treatment.

    Inclusion criterion 10

    (3)Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) before the first dose of the investigational drug.

    Exclusion criterion 3

    (9)Post-implantation of a stent in the digestive tract (referring to the muscular tube from the mouth to the anal canal, including the mouth, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, appendix, colon, rectum), and anal canal) or trachea. (Excluding stent placement included as part of radical surgery, such as duodenal stent placement in subjects with pancreatic head cancer.)

    Exclusion criterion 9

    (15)Previously received antibody-drug conjugate therapy based on topoisomerase inhibitors.

    Exclusion criterion 15

  3. (7)Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.

    Inclusion criterion 7

  4. (4)Confirmed borderline resectable pancreatic cancer as assessed by imaging (abdominal contrast-enhanced CT or contrast-enhanced MRI), with resectability determined according to the NCCN 2025.V2 guidelines for pancreatic cancer.

    Inclusion criterion 4

  5. (12)History of other primary malignancies.

    Exclusion criterion 12

  6. (19)Pregnant or breastfeeding female subjects.

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07415525, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • (1)Sign a written Informed Consent Form (ICF), willing and able to comply with the visits and related procedures specified in the protocol.
  • (2)Histopathologically confirmed pancreatic adenocarcinoma.
  • (3)No evidence of distant metastasis as assessed by imaging (must include chest, abdomen, and pelvis). Bone scan or PET/CT may be performed for confirmation if necessary.
  • (4)Confirmed borderline resectable pancreatic cancer as assessed by imaging (abdominal contrast-enhanced CT or contrast-enhanced MRI), with resectability determined according to the NCCN 2025.V2 guidelines for pancreatic cancer.
  • (5)No prior anti-tumor treatment for the studied disease, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.
  • (6)Age ≥18 years and ≤75 years, regardless of gender.
  • (7)Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
  • (8)Expected survival ≥12 weeks.
  • (9)Adequate bone marrow and organ function.
  • (10)Female subjects of childbearing potential or male subjects with female partners of childbearing potential must use effective contraception throughout the treatment period and for 6 months after treatment.
  • (11)Confirmed *CLDN18.2 positivity by pathological tissue testing. *CLDN18.2 positivity is defined as Claudin18.2 immunohistochemical membrane staining intensity ≥1+ in ≥50% of tumor cells, accepting previous test results, results from the research center, or laboratory test results. Regarding the proportion of CLDN18.2 expression, the investigator and sponsor may dynamically adjust the criteria during the study based on newly generated data and data from other studies.

Exclusion Criteria:

  • (1)Currently participating in another interventional clinical study, excluding observational (non-interventional) clinical studies or being in the survival follow-up phase of an interventional study.
  • (2)The tumor is a locally recurrent lesion.
  • (3)Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) before the first dose of the investigational drug.
  • (4)Underwent biliary stent implantation or PTCD within 7 days before the first dose of the investigational drug.
  • (5)Received any live vaccine within 4 weeks before the first dose of the investigational drug or plans to receive one during the study period.
  • (6)Underwent major surgical procedures (craniotomy, thoracotomy, laparotomy, or other surgeries defined by the investigator, excluding needle biopsy) within 4 weeks before the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study period.
  • (7)History of gastrointestinal perforation and/or fistula within the past 6 months before the first dose of the investigational drug, which has not been resolved through surgical treatment.
  • (8)Pyloric obstruction affecting eating or gastric emptying that cannot be improved by jejunal feeding tube placement.
  • (9)Post-implantation of a stent in the digestive tract (referring to the muscular tube from the mouth to the anal canal, including the mouth, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, appendix, colon, rectum), and anal canal) or trachea. (Excluding stent placement included as part of radical surgery, such as duodenal stent placement in subjects with pancreatic head cancer.)
  • (10)Interstitial lung disease requiring steroid treatment, or a history of interstitial lung disease, non-infectious pneumonia, severely impaired lung function, or uncontrolled pulmonary conditions such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspicion of the above conditions during screening.
  • (11)Presence of uncontrolled diseases.
  • (12)History of other primary malignancies.
  • (13)Known history of immunodeficiency.
  • (14)History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • (15)Previously received antibody-drug conjugate therapy based on topoisomerase inhibitors.
  • (16)For subjects receiving medication, a history of allergy to the corresponding drug or formulation.
  • (17)For subjects receiving medication, contraindications to the corresponding drug.
  • (18)For subjects receiving medication, a history of permanent discontinuation of the corresponding drug due to adverse reactions.
  • (19)Pregnant or breastfeeding female subjects.
  • (20)Other conditions considered by the investigator as not suitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07415525, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07415525, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07415525